Inhibikase Therapeutics (NYSE:IKT – Get Free Report) will issue its quarterly earnings data after the market closes on Tuesday, November 14th. Analysts expect the company to announce earnings of ($1.12) per share for the quarter. Parties interested in listening to the company’s conference call can do so using this link.
Inhibikase Therapeutics (NYSE:IKT – Get Free Report) last issued its quarterly earnings data on Monday, August 14th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.19). Inhibikase Therapeutics had a negative return on equity of 83.69% and a negative net margin of 7,551.59%. The firm had revenue of $0.12 million for the quarter. On average, analysts expect Inhibikase Therapeutics to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.
Inhibikase Therapeutics Price Performance
Shares of NYSE:IKT opened at $1.00 on Friday. Inhibikase Therapeutics has a 12-month low of $0.79 and a 12-month high of $6.94. The business has a 50 day moving average of $1.24 and a 200-day moving average of $2.63. The stock has a market cap of $5.35 million, a PE ratio of -0.24 and a beta of 1.00.
Analysts Set New Price Targets
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of IKT. Barclays PLC acquired a new position in shares of Inhibikase Therapeutics during the second quarter worth $41,000. Renaissance Technologies LLC boosted its position in Inhibikase Therapeutics by 17.7% during the second quarter. Renaissance Technologies LLC now owns 221,900 shares of the company’s stock valued at $165,000 after acquiring an additional 33,431 shares during the last quarter. Blair William & Co. IL grew its stake in shares of Inhibikase Therapeutics by 20.5% in the 1st quarter. Blair William & Co. IL now owns 276,000 shares of the company’s stock valued at $181,000 after buying an additional 47,000 shares during the period. Vanguard Group Inc. increased its holdings in shares of Inhibikase Therapeutics by 10.7% during the first quarter. Vanguard Group Inc. now owns 530,098 shares of the company’s stock valued at $785,000 after acquiring an additional 51,394 shares in the last quarter. Finally, Armistice Capital LLC bought a new stake in shares of Inhibikase Therapeutics during the first quarter valued at approximately $1,947,000. 13.99% of the stock is currently owned by institutional investors and hedge funds.
Inhibikase Therapeutics Company Profile
Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.
- Five stocks we like better than Inhibikase Therapeutics
- Bank Stocks – Best Bank Stocks to Invest In
- MarketBeat Week in Review – 11/6 – 11/10
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Data giants MongoDB and Snowflake just got upgraded
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Plug Power at tipping point; it’s make or break time for hydrogen
Receive News & Ratings for Inhibikase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibikase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.